Chest Medicine
Impact of SARS-CoV-2 variants on inpatient clinical outcome
17 Jan, 2023 | 13:21h | UTCImpact of SARS-CoV-2 variants on inpatient clinical outcome – Clinical Infectious Diseases
Review | Viral infections in critical care
17 Jan, 2023 | 13:01h | UTCViral infections in critical care: a narrative review – Anaesthesia
WHO updates COVID-19 guidelines on masks, treatments and patient care
15 Jan, 2023 | 20:44h | UTCWHO updates COVID-19 guidelines on masks, treatments and patient care – World Health Organization
WHO Updated Guidelines:
Therapeutics and COVID-19: Living guideline, 13 January 2023 – World Health Organization
RCT | Fluvoxamine no better than placebo in outpatients with mild to moderate COVID-19
15 Jan, 2023 | 20:37h | UTCEditorial: Lack of Benefit of Fluvoxamine for COVID-19 – JAMA
Author Interview: Fluvoxamine vs Placebo and Time to Sustained Recovery From Mild or Moderate COVID-19 – JAMA
Commentary: Trial finds that fluvoxamine doesn’t speed COVID recovery – CIDRAP
Commentary on Twitter
Among outpatients with mild to moderate #COVID19, treatment with 50 mg of fluvoxamine twice daily for 10 days, compared with placebo, did not improve time to sustained recovery. https://t.co/4QgBssqFSU pic.twitter.com/RMZ6mqlx6u
— JAMA (@JAMA_current) January 12, 2023
Review | Management of thoracic trauma
15 Jan, 2023 | 19:44h | UTCManagement of thoracic trauma – Anaesthesia
Retrospective Study | Most patients with long Covid developed after mild infection get better within a year
13 Jan, 2023 | 13:42h | UTCLong covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study – The BMJ
News Release: Most long COVID effects resolve within a year after mild infection, finds study- British Medical Journal
Commentary: Long COVID After Mild Infection? It Fades Within a Year – HealthDay
Study identified six clusters of patients with long COVID, with distinct profiles of phenotypic abnormalities
13 Jan, 2023 | 13:40h | UTCGeneralisable long COVID subtypes: Findings from the NIH N3C and RECOVER programmes – eBioMedicine
RCT | A 24-week, all-oral regimen for rifampin-resistant tuberculosis
12 Jan, 2023 | 13:27h | UTCA 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis – New England Journal of Medicine
Commentary: Trial results show superiority of shorter, all-oral treatment for drug-resistant TB – CIDRAP
WHO consolidated guidelines on tuberculosis | Drug-resistant tuberculosis treatment, 2022 update
12 Jan, 2023 | 13:30h | UTCSee also:
– WHO consolidated guidelines on tuberculosis: module 1: prevention: tuberculosis preventive treatment
RCT | Early treatment with Molnupiravir did not reduce hospitalizations in high-risk adults with COVID-19
12 Jan, 2023 | 13:24h | UTCCommentaries:
Molnupiravir doesn’t cut Omicron hospitalization, death but can speed recovery – CIDRAP
SR | Interventions for the eradication of methicillin‐resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis
12 Jan, 2023 | 13:04h | UTC
Review | Durability of vaccine-induced and natural immunity against COVID-19
11 Jan, 2023 | 14:29h | UTC
SR | Efficacy of presurgical interventions to promote smoking cessation
11 Jan, 2023 | 14:24h | UTC
Ten rules for optimizing ventilatory settings and targets in post-cardiac arrest patients
11 Jan, 2023 | 14:13h | UTC
Special Issue | Imaging the critically ill
10 Jan, 2023 | 14:10h | UTCHomepage: Imaging the Critically Ill
The Use of Critical Care Ultrasound
The Role of Lung Imaging to Personalise Lung Ventilation in ARDS Patients
Imaging the Critically Ill Patient: Echocardiography
Point of Care Ultrasound: The Critical Imaging Tool for the Critically Unwell
Rapid Assessment of Fluid Responsiveness and Tolerance With Ultrasound of the Neck Vessels
POCUS in Critical Care Physiotherapy: Give Me Sight Beyond Sight
Review | Home monitoring in interstitial lung diseases
10 Jan, 2023 | 14:06h | UTCHome monitoring in interstitial lung diseases – The Lancet Respiratory Diseases
Machine learning in radiology: the new frontier in interstitial lung diseases
10 Jan, 2023 | 14:08h | UTC
RCT | VV116 vs. Nirmatrelvir–Ritonavir for oral treatment of Covid-19
9 Jan, 2023 | 14:50h | UTCVV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19 – New England Journal of Medicine
Commentaries:
Study could pave way for new antiviral, as China grapples with Covid wave – STAT
Chinese oral COVID-19 drug equally effective with Paxlovid: study
VV116 Noninferior to Nirmatrelvir-Ritonavir for COVID-19 – HealthDay
Commentary on Twitter
In a Chinese trial involving participants with symptomatic mild-to-moderate Covid-19, VV116 (an oral analogue of remdesivir) was noninferior to nirmatrelvir–ritonavir with respect to the time to sustained clinical recovery.
Read the full study: https://t.co/zckTB3Rvb9 pic.twitter.com/0TVF7hEXjP
— NEJM (@NEJM) December 28, 2022
Review | Voice restoration in mechanically ventilated intensive care unit patients with a tracheostomy
9 Jan, 2023 | 13:44h | UTC
RCT | Efficacy and safety of azithromycin vs. placebo to treat lower respiratory tract infections associated with low procalcitonin.
16 Dec, 2022 | 13:30h | UTCEfficacy and safety of azithromycin versus placebo to treat lower respiratory tract infections associated with low procalcitonin: a randomised, placebo-controlled, double-blind, non-inferiority trial – The Lancet Infectious Diseases (link to abstract – $ for full-text)
Commentary on Twitter
New research: Efficacy and safety of azithromycin versus placebo to treat lower respiratory tract infections associated with low procalcitonin: a randomised, placebo-controlled, double-blind, non-inferiority trialhttps://t.co/EZW7YdxPPU pic.twitter.com/4zlsVN5NtT
— The Lancet Infectious Diseases (@TheLancetInfDis) December 14, 2022
SR | Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis.
13 Dec, 2022 | 14:15h | UTCInhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis – Cochrane Library
Summary: Inhaling antibiotics to treat lung infection in people with cystic fibrosis – Cochrane Library
Review | Chest wall loading in the ICU: pushes, weights, and positions.
13 Dec, 2022 | 14:14h | UTCChest wall loading in the ICU: pushes, weights, and positions – Annals of Intensive Care
RCT | Twice-daily oral zinc in the treatment of patients with COVID-19.
12 Dec, 2022 | 12:48h | UTC
Review | Parasitic lung diseases.
12 Dec, 2022 | 12:32h | UTCParasitic lung diseases – European Respiratory Review
Cohort Study | Tobacco use and incidence of adverse oral health outcomes.
12 Dec, 2022 | 12:30h | UTCCommentary: Expert reaction to study looking at smoking, vaping and oral health – Science Media Centre